| Autor: |
C, Rosak, R, Petzoldt, R, Wolf, T, Reblin, B, Dehmel, D, Seidel |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
International journal of clinical practice. 59(10) |
| ISSN: |
1368-5031 |
| Popis: |
This study investigated the efficacy during daily practice of rosiglitazone (RSG) added to metformin (MET) in poorly controlled type 2 diabetes mellitus. Two post-marketing observational studies were conducted in Germany over 6 months. RSG (4 mg/day titrated to 8 mg/day as required) was added to existing MET in 11,014 subjects. Subjects were maintained on diet and exercise. Addition of RSG to MET significantly reduced median HbA 1c by 1.3% (8.1 vs. 6.8%; p0.0001) and median fasting blood glucose (FBG) by 47.0 mg/dl (171.0 vs. 124.0 mg/dl; p0.0001) after 6 months. The proportion of subjects achieving HbA(1c) targets ofor = 6.5 andor = 7.0% increased from 3.5 to 38.8% and from 13.5 to 63.7%, respectively. Mean systolic and diastolic blood pressure decreased by 7 and 3 mmHg, respectively (p0.0001). Mean weight decreased by 1.7 kg and was constant or reduced in most (74.1%) subjects. Addition of RSG to MET significantly reduces median HbA 1c and FBG in clinical practice and is generally well tolerated. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
